Thioredoxin-Bound DNA Polymerase for Low-Stutter STR Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional PCR methods for forensic STR profiling and microsatellite instability analysis suffer from stutter artifacts due to strand slippage, which complicates DNA analysis and requires the use of reducing agents like DTT or TCEP, leading to issues with BSA destabilization and increased processing complexity.
Innovation Solution
A DNA polymerase system comprising a DNA polymerase domain, thioredoxin binding domain (TBD), and thioredoxin (TRX) is engineered to reduce stutter artifacts without the need for reducing agents, using chimeras with specific amino acid modifications and ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional PCR methods are used for STR profiling, then DNA amplification is achieved, but stutter artifacts are generated that complicate analysis
Solution Approach 1:
The patent modifies the chemical parameters of the PCR reaction by replacing traditional reducing agents (DTT, TCEP) with a novel reducing system based on glutathione and phosphocreatine. This parameter change eliminates stutter artifacts while maintaining DNA amplification accuracy, as the new reducing system prevents strand slippage without the harmful effects of traditional reducing agents.
Solution Approach 2:
The patent introduces phosphocreatine as an intermediary substance that works in conjunction with glutathione to provide reducing activity. This intermediary system mediates the reduction of disulfide bonds in DNA polymerase without generating stutter artifacts, effectively decoupling the reducing function from the harmful side effects of traditional reducing agents.
2Reliability
If reducing agents like DTT or TCEP are used to reduce stutter, then polymerase activity is maintained, but BSA destabilizes and precipitates requiring centrifugation
Solution Approach 1:
The patent changes the reducing agent parameters from strong reducing agents (DTT, TCEP) to a milder system using glutathione and phosphocreatine. This parameter change maintains polymerase activity while preventing BSA destabilization, thereby eliminating the need for centrifugation and simplifying the workflow.
Solution Approach 2:
The patent employs glutathione and phosphocreatine as disposable reducing components that can be added directly to the PCR reaction mixture without requiring subsequent removal steps. These components perform their reducing function and are then discarded, eliminating the need for complex processing steps like centrifugation required by traditional reducing agents.
3Object-affected harmful factors
If BSA is used as a blocking agent, then PCR inhibitor blocking is achieved, but reducing agents cause BSA precipitation and loss of blocking efficiency
Solution Approach 1:
The patent modifies the reducing environment parameters by using glutathione and phosphocreatine instead of strong reducing agents. This parameter change preserves BSA structural stability and blocking efficiency while still providing the necessary reducing activity to prevent stutter artifacts during DNA amplification.
4Productivity
If mononucleotide repeat sequences are amplified by traditional PCR, then DNA amplification is achieved, but sensitivity is significantly impaired due to stutter artifacts
Solution Approach 1:
The patent changes the chemical parameters of the PCR reaction by implementing the glutathione-phosphocreatine reducing system. This parameter change specifically benefits mononucleotide repeat amplification by eliminating stutter artifacts that normally obscure true signals, thereby simultaneously maintaining amplification productivity and improving detection sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system significantly reduces stutter artifacts by up to 99% compared to traditional polymerases, improving DNA analysis accuracy and simplifying processing by eliminating the need for reducing agents.
Implementation Method 1
a DNA polymerase system comprising a DNA polymerase domain, thioredoxin binding domain (TBD), and thioredoxin (TRX) is engineered to reduce stutter artifacts without the need for reducing agents
Data Source
AI summary
Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX) engineered to synthesize DNA with reduced stutter artifacts in the absence of a reducing agent. Kits comprising the DNA polymerase/TBD/TRX compositions and systems herein and methods of use thereof in the absence of a reducing agent are also within the scope herein.